MyFinsight
Home
Blog
About
Contact
Download
Download image
Investments
$3,204M
(-37.15%↓ Y/Y)
Cash and cash
equivalents
$2,595M
(34.67%↑ Y/Y)
Prepaid expenses and
other current assets
$408M
(-31.89%↓ Y/Y)
Accounts receivable, net
$184M
(-48.60%↓ Y/Y)
Inventory
$153M
(30.77%↑ Y/Y)
Total current assets
$6,544M
(-19.20%↓ Y/Y)
Investments, non-current
$2,336M
(-6.34%↓ Y/Y)
Property, plant and
equipment, net
$2,134M
(-2.82%↓ Y/Y)
Right-of-use assets,
operating leases
$719M
(-5.27%↓ Y/Y)
Other non-current
assets
$605M
(1.85%↑ Y/Y)
Total assets
$12,338M
(-12.76%↓ Y/Y)
Total liabilities and
stockholders equity
$12,338M
(-12.76%↓ Y/Y)
Total stockholders
equity
$8,650M
(-20.65%↓ Y/Y)
Total liabilities
$3,688M
(13.79%↑ Y/Y)
Retained earnings
$7,223M
(-28.09%↓ Y/Y)
Additional paid-in capital
$1,382M
(59.58%↑ Y/Y)
Accumulated other
comprehensive income (loss)
$45M
(550.00%↑ Y/Y)
Total current
liabilities
$1,987M
(-9.93%↓ Y/Y)
Operating lease
liabilities, non-current
$653M
(-2.68%↓ Y/Y)
Long-term debt
$590M
Other non-current
liabilities
$285M
(6.74%↑ Y/Y)
Deferred revenue,
non-current
$153M
(163.79%↑ Y/Y)
Financing lease
liabilities, non-current
$20M
(-48.72%↓ Y/Y)
Accrued liabilities
$1,386M
(-2.87%↓ Y/Y)
Accounts payable
$317M
(-21.73%↓ Y/Y)
Other current
liabilities
$185M
(-16.29%↓ Y/Y)
Deferred revenue
$99M
(-35.29%↓ Y/Y)
Back
Back
Balance Sheet
source: myfinsight.com
Master Final R&D Day 2021 Slides (09
Moderna, Inc. (MRNA)
Master Final R&D Day 2021 Slides (09
Moderna, Inc. (MRNA)